×
About 1,605 results

ALLMedicine™ Factor X Center

Research & Reviews  550 results

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Hav...
https://clinicaltrials.gov/ct2/show/NCT05461807

Jul 27th, 2022 - This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions. People with VTE ha...

Treatment of Hemophilia A Patients With FVIII Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04023019

Jul 25th, 2022 - This study will capture different approaches in the management of persons with haemophilia A (HA) and inhibitors. HA is a serious blood coagulation disorder caused by a deficiency in FVIII that results in a failure to produce FVIII in sufficient q...

Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a ...
https://doi.org/10.1016/j.leukres.2022.106917
Leukemia Research; Gao YJ, Shen KN et. al.

Jul 19th, 2022 - Factor X (FX) deficiency is prevalent in light-chain (AL) amyloidosis but its clinical significance was not investigated deeply. We conducted a retrospective analysis of a consecutive cohort with 207 primary AL amyloidosis patients. FX deficiency ...

Hsa_circ_0030042 Ameliorates Oxidized Low-Density Lipoprotein-Induced Endothelial Cell ...
https://doi.org/10.1536/ihj.22-065
International Heart Journal; Yu L, Ma W et. al.

Jul 14th, 2022 - Atherosclerosis (AS) is a common etiology of cardiovascular disease. As an emerging functional biomarker, circular RNAs (circRNAs) are involved in various diseases, including cardiovascular disease. However, the mechanism of action of circ_0030042...

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
https://clinicaltrials.gov/ct2/show/NCT04349189

Jul 7th, 2022 - Venous thromboembolism (VTE) the third most frequent cause of vascular mortality after myocardial infarction and stroke, occurs more frequently among Americans of African descent compared with other ethnic minorities in the US. VTEs are provoked b...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  42 results

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Hav...
https://clinicaltrials.gov/ct2/show/NCT05461807

Jul 27th, 2022 - This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions. People with VTE ha...

Treatment of Hemophilia A Patients With FVIII Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04023019

Jul 25th, 2022 - This study will capture different approaches in the management of persons with haemophilia A (HA) and inhibitors. HA is a serious blood coagulation disorder caused by a deficiency in FVIII that results in a failure to produce FVIII in sufficient q...

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
https://clinicaltrials.gov/ct2/show/NCT04349189

Jul 7th, 2022 - Venous thromboembolism (VTE) the third most frequent cause of vascular mortality after myocardial infarction and stroke, occurs more frequently among Americans of African descent compared with other ethnic minorities in the US. VTEs are provoked b...

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
https://clinicaltrials.gov/ct2/show/NCT04516941

Jun 28th, 2022 - There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF). Post-Morten observat...

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
https://clinicaltrials.gov/ct2/show/NCT04767776

May 25th, 2022 - Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning. A recent study, in healthy subjects, shows...

see more →

News  45 results

'It's an Amazing Time to Be a Hemophilia Provider'
https://www.medscape.com/viewarticle/974738

May 27th, 2022 - New medications such as emicizumab (Hemlibra) are transforming the lives of patients with hemophilia A, and more treatments are in the pipeline. "It's an amazing time to be a hemophilia provider," Alice D. Ma, MD, University of North Carolina at C...

Specialists hail new era in hemophilia treatment
https://www.mdedge.com/hematology-oncology/article/254950/bleeding-disorders/specialists-hail-new-era-hemophilia-treatment
Randy Dotinga

May 25th, 2022 - New medications such as emicizumab (Hemlibra) are transforming the lives of patients with hemophilia A, and more treatments are in the pipeline. “It’s an amazing time to be a hemophilia provider,” Alice D.

Emicizumab effective in children with hemophilia A and inhibitors
https://www.mdedge.com/hematology-oncology/article/210977/bleeding-disorders/emicizumab-effective-children-hemophilia-and
Andrew D. Bowser

Oct 27th, 2019 - Emicizumab (Hemlibra) is well tolerated and has substantial, clinically meaningful efficacy in pediatric patients with hemophilia A and factor VIII inhibitors, according to an analysis of data from the HAVEN 2 trial in this bispecific humanized mo.

ASCO VTE guideline update: DOACs now an option for prevention, treatment
https://www.mdedge.com/hematology-oncology/article/206647/thrombosis/asco-vte-guideline-update-doacs-now-option-prevention
Sharon Worcester

Aug 19th, 2019 - The direct oral anticoagulants (DOACs) apixaban and rivaroxaban are now among the options for thromboprophylaxis in high-risk cancer outpatients with low risk for bleeding and drug interactions, according to a practice guideline update from the Am.

Andexanet alfa effectively reverses factor Xa inhibition
https://www.mdedge.com/cardiology/article/196564/stroke/andexanet-alfa-effectively-reverses-factor-xa-inhibition
Erik Greb

Mar 18th, 2019 - HONOLULU – Andexanet alfa rapidly reverses factor Xa inhibition and effectively establishes hemostasis in patients with acute major bleeding, according to a study presented at the International Stroke Conference sponsored by the American Heart Ass.

see more →